HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $19
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $14 to $19.
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $14 to $19.